Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. (Q43504840)
Jump to navigation
Jump to search
scientific article published on 10 June 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. |
scientific article published on 10 June 2009 |
Statements
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived (English)
Alessandro Corso
Silvia Mangiacavalli
Patrizia Zappasodi
Gian Matteo Pica
Alessandra Algarotti
Cristiana Pascutto